Cyclo Therapeutics Inc

NASDAQ CYTH

Download Data

Cyclo Therapeutics Inc Interest Expense To Sales 5 year CAGR for the quarter ending December 31, 2023: -71.04%

Cyclo Therapeutics Inc Interest Expense To Sales 5 year CAGR is -71.04% for the quarter ending December 31, 2023. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Cyclo Therapeutics Inc Interest Expense To Sales for the quarter ending March 31, 2023 was -0.03%, a -100.00% change year over year.
  • Cyclo Therapeutics Inc Interest Expense To Sales for the quarter ending March 31, 2022 was 83,561,996.81%.
NASDAQ: CYTH

Cyclo Therapeutics Inc

CEO Mr. N. Scott Fine
IPO Date Feb. 23, 2011
Location United States
Headquarters 6714 NW 16th Street, Gainesville, FL, United States, 32653
Employees 8
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Similar companies

PAHC

Phibro Animal Health Corporation

NA

NA

EGRX

Eagle Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email